Law ❯ Securities Law ❯ Regulatory Compliance ❯ FDA Regulations

Drug Approval Process

Savara Investors Pressed to Meet Class-Action Deadlines Over Alleged MOLBREEVI BLA Deficiencies

Lead-plaintiff motions are due this week in suits alleging Savara’s filing lacked required chemistry, manufacturing and controls information.

Cytokinetics Investors Face Nov. 17 Deadline to Seek Lead Role in Aficamten Securities Case

Cytokinetics Investors Urged to Seek Counsel Before Nov. 17 Lead-Plaintiff Deadline in Aficamten Case

Cytokinetics Faces Investor Class Action Over Aficamten REMS Disclosures as Lead-Plaintiff Deadline Nears